Affomix Collaborates With City of Hope

Under the collaboration, Affomix is expected to use its automated antibody selection technology to provide City of Hope with recombinant antibodies that are designed to be readily tagged with oligonucleotide ‘zipcodes’, making them compatible with sequencers.

John Boyce, head of business development for Affomix and co-founder of Delphi Bio, said: “These specialised antibodies, which are designed to enable sensitive detection and accurate quantitation, are ideal for use in several existing platforms, including next generation sequencers. Collaborations with City of Hope will enable us to expand our reach into the clinical diagnostics and personalised medicine markets. This is a transformative milestone in the merging of proteomics and genomics.”

Michael Sherman, president of Affomix, said: “We are pleased to be working with an innovative partner such as City of Hope. The institution’s ability to couple research programs with diagnostic test development is well documented. This collaboration will expand our efforts to extend the logical progression from nucleic acid-based to protein-based diagnostic analysis.”